Since the identification in early 2013 of severe disease caused by influenza A(H7N9) virus infection, there have been few attempts to characterize the full severity profile of human infections. Our objective was to estimate the number and severity of H7N9 infections in Guangzhou, using a serological study. We collected residual sera from patients of all ages admitted to a hospital in the city of Guangzhou in southern China in 2013 and 2014. We screened the sera using a haemagglutination inhibition assay against a pseudovirus containing the H7 and N9 of A/Anhui/1/2013(H7N9), and samples with a screening titer ≥10 were further tested by standard hemagglutination-inhibition and virus neutralization assays for influenza A(H7N9). We used a statistical model to interpret the information on antibody titers in the residual sera, assuming that the residual sera provided a representative picture of A(H7N9) infections in the general population, accounting for potential cross-reactions. We collected a total of 5360 residual sera from December 2013 to April 2014 and from October 2014 to December 2014, and found two specimens that tested positive for H7N9 antibody at haemagglutination inhibition titer ≥40 and a neutralization titer ≥40. Based on this, we estimated that 64,000 (95 % credibility interval: 7300, 190,000) human infections with influenza A(H7N9) virus occurred in Guangzhou in early 2014, with an infection-fatality risk of 3.6 deaths (95 % credibility interval: 0.47, 15) per 10,000 infections. Our study suggested that the number of influenza A(H7N9) virus infections in Guangzhou substantially exceeded the number of laboratory-confirmed cases there, albeit with considerable imprecision. Our study was limited by the small number of positive specimens identified, and larger serologic studies would be valuable. Our analytic framework would be useful if larger serologic studies are done.
16 October 2025 in World Allergy Organization Journal
Bronchial asthma is a heterogeneous inflammatory airway disease with complex etiology. While the respiratory microbiome and host metabolism are implicated, their integrated roles in defining asthma subtypes remain underexplored. This multi-omics study utilized 16S rRNA sequencing and untargeted metabolomics on sputum samples from asthma patients and healthy controls. We characterized airway microbial and metabolic profiles, identified asthma subgroups through unsupervised clustering, and investigated microbe-metabolite interactions. Asthma patients exhibited typical clinical hallmarks including elevated IgE and impaired lung function. Microbiome analysis revealed significant enrichment of Streptococcus, Veillonella, and Prevotella as key asthma-associated taxa, alongside dysregulation of crucial lipid metabolic pathways (eg, alpha-linolenic and arachidonic acid). Four highly discriminative diagnostic biomarkers (AUC >0.9), including cis-aconitic acid and LPE 20:1, were identified, indicating specific metabolic perturbations. Unsupervised clustering stratified asthma patients into 2 distinct endotypes: a severe Streptococcus-dominant cluster (Cluster 1) with profound systemic and local metabolic disturbances, and a milder cluster (Cluster 2) with microbial and metabolic profiles resembling healthy controls. These endotypes displayed differential lipid and amino acid metabolism, suggesting unique underlying mechanisms. Our findings precisely delineate asthma endotypes driven by distinct microbiome-metabolome interactions, providing novel diagnostic biomarkers and pathway-specific therapeutic targets. This study critically advances our understanding of asthma heterogeneity, highlighting the importance of integrated multi-omics for personalized precision medicine strategies. Not applicable.
Preoperative infection in urolithiasis patients poses significant risks for surgical complications. Traditional urine culture methods have limitations in d